CDKN2A and neoplasm: This suggests that CAFs of various subtypes in the tumor environment may enter a state of senescence, in which they cease to proliferate, activate senescence markers including SA-βGal and the cell cycle inhibitors p16 and p21, and acquire the senescence-associated gene-expression programs.